A detailed history of Legal & General Group PLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 34,022 shares of FDMT stock, worth $188,822. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,022
Previous 34,022 -0.0%
Holding current value
$188,822
Previous $367,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $29,576 - $74,473
2,736 Added 8.75%
34,022 $367,000
Q2 2024

Aug 14, 2024

BUY
$20.93 - $30.01 $127,652 - $183,030
6,099 Added 24.21%
31,286 $656,000
Q1 2024

Jul 01, 2024

BUY
$17.03 - $35.87 $22,428 - $47,240
1,317 Added 5.52%
25,187 $802,000
Q1 2024

May 14, 2024

SELL
$17.03 - $35.87 $11,563 - $24,355
-679 Reduced 2.77%
23,870 $760,000
Q4 2023

Feb 15, 2024

BUY
$9.76 - $21.25 $1,346 - $2,932
138 Added 0.57%
24,549 $497,000
Q3 2023

Nov 14, 2023

BUY
$12.64 - $19.76 $2,970 - $4,643
235 Added 0.97%
24,411 $310,000
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $259,357 - $397,932
17,108 Added 242.05%
24,176 $436,000
Q1 2023

May 15, 2023

BUY
$15.45 - $23.19 $65,229 - $97,908
4,222 Added 148.35%
7,068 $121,000
Q4 2022

Feb 14, 2023

SELL
$6.85 - $25.46 $44,805 - $166,533
-6,541 Reduced 69.68%
2,846 $63,000
Q2 2022

Aug 22, 2022

BUY
$5.68 - $15.99 $6,514 - $18,340
1,147 Added 13.92%
9,387 $66,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $53,496 - $90,090
2,735 Added 49.68%
8,240 $181,000
Q3 2021

Nov 15, 2021

BUY
$22.73 - $36.04 $106,626 - $169,063
4,691 Added 576.29%
5,505 $149,000
Q2 2021

Aug 12, 2021

BUY
$22.2 - $42.29 $488 - $930
22 Added 2.78%
814 $20,000
Q1 2021

May 17, 2021

BUY
$35.94 - $52.67 $28,464 - $41,714
792 New
792 $34,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $180M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.